Related Experiment Video
Updated: Jan 8, 2026

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
TL1A blockade in inflammatory bowel diseases: Clinical trials to watch
Ferdinando D'Amico1, Laurent Peyrin-Biroulet2, Vipul Jairath3
1IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Department of Gastroenterology and Endoscopy, 20132 Milan, Italy.
Abstract:
TL1A inhibitors offer a novel therapeutic strategy in inflammatory bowel disease by combining anti-inflammatory effects with potential antifibrotic activity. Phase 2 studies show clinical efficacy and a favorable safety profile. Ongoing phase 3 trials will further define their role, including the utility of genetic predictors to guide patient-specific therapy.
Insights
Tumor necrosis factor-like ligand 1A (TL1A) inhibitors show promise for treating inflammatory bowel disease. These agents possess anti-inflammatory and antifibrotic properties, with ongoing trials confirming their efficacy and safety.
Area of Science:
- Gastroenterology and Immunology
Background:
- Inflammatory bowel disease (IBD) presents significant challenges, necessitating novel therapeutic approaches.
- Fibrosis is a key complication in IBD, contributing to disease progression and poor outcomes.
Purpose of the Study:
- To evaluate the therapeutic potential of TL1A inhibitors in IBD.
- To assess the combined anti-inflammatory and antifibrotic effects of TL1A inhibition.
Main Methods:
- Clinical efficacy and safety were assessed in Phase 2 studies.
- Ongoing Phase 3 trials are investigating the role of TL1A inhibitors in patient populations.
Main Results:
- Phase 2 studies demonstrated clinical efficacy for TL1A inhibitors.
- A favorable safety profile was observed in early-phase trials.
- Genetic predictors are being explored to personalize TL1A inhibitor therapy.
Conclusions:
- TL1A inhibitors represent a promising new therapeutic strategy for IBD.
- The dual action of anti-inflammation and antifibrosis offers a unique advantage.
- Future research, including Phase 3 trials and genetic profiling, will refine patient selection and treatment protocols.
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...